Tumor Marker–Guided PET in Breast Cancer Patients—A Recipe for a Perfect Wedding
- 1 May 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Nuclear Medicine
- Vol. 37 (5), 467-474
- https://doi.org/10.1097/rlu.0b013e31824850b0
Abstract
Introduction: Early detection of breast cancer (BC) recurrence is a fundamental issue during follow-up. Although the utilization of new therapeutic protocols aimed at reducing the recurrence risk is defined, the diagnostic approach for early detection remains to be clarified. We aim to provide a critical overview of recently published reports and perform a meta-analysis on the use of tumor markers in BC patients as a guide for fluorodeoxyglucose positron emission tomography (PET) imaging. Methods: Medline and Google Scholar were used for searching English and non-English articles that evaluate the role of PET in BC recurrence when an increase in tumor markers is found. All complete studies were reviewed; thus, quantitative and qualitative analyses were performed. Results: From 2001 to May 2011, we found 19 complete articles that critically evaluated the role of PET in BC recurrence detection in the presence of elevated tumor markers. The meta-analysis of the 13 studies provided the following results: pooled sensitivity 0.878 (95% CI: 0.838-0.909), pooled specificity 0.693 (95% CI: 0.553-0.805), and pooled accuracy 0.828 (95% CI: 0.762-0.878). Conclusions: The current experience confirms the potential of fluorodeoxyglucose PET, and in particular of PET/CT, in detecting occult soft tissue and bone metastases in the presence of a progressive increase of serum tumor markers in BC patients, but this should be better defined in the current practical recommendations.Keywords
This publication has 42 references indexed in Scilit:
- 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: A multicentre studyEuropean Journal of Radiology, 2011
- Could the serial determination of Ca15.3 serum improve the diagnostic accuracy of PET/CT? Results from small population with previous breast cancerAnnals of Nuclear Medicine, 2011
- Breast cancer recurrence diagnosis suspected on tumor marker risingCancer, 2010
- Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic dataBMC Medical Research Methodology, 2009
- FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2009
- Periodic Measurement of Serum Carcinoembryonic Antigen and Carbohydrate Antigen 15-3 Levels as Postoperative Surveillance After Breast Cancer SurgerySurgery Today, 2005
- Impact of FDG PET on Defining the Extent of Disease and on the Treatment of Patients with Recurrent or Metastatic Breast CancerAmerican Journal of Roentgenology, 2004
- Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPAEuropean Journal Of Cancer, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003